nodes	percent_of_prediction	percent_of_DWPC	metapath
Tafluprost—PTGS2—pancreatic cancer	0.829	1	CbGaD
Tafluprost—Uveitis—Erlotinib—pancreatic cancer	0.00441	0.085	CcSEcCtD
Tafluprost—Common cold—Fluorouracil—pancreatic cancer	0.00403	0.0778	CcSEcCtD
Tafluprost—Eyelid oedema—Sunitinib—pancreatic cancer	0.00264	0.051	CcSEcCtD
Tafluprost—Visual acuity reduced—Tamoxifen—pancreatic cancer	0.00262	0.0505	CcSEcCtD
Tafluprost—Cataract—Tamoxifen—pancreatic cancer	0.00164	0.0316	CcSEcCtD
Tafluprost—Lacrimation increased—Sunitinib—pancreatic cancer	0.00145	0.0279	CcSEcCtD
Tafluprost—Dry eye—Erlotinib—pancreatic cancer	0.00142	0.0274	CcSEcCtD
Tafluprost—Eye irritation—Fluorouracil—pancreatic cancer	0.00123	0.0238	CcSEcCtD
Tafluprost—Lacrimation increased—Irinotecan—pancreatic cancer	0.00119	0.023	CcSEcCtD
Tafluprost—Lacrimation increased—Fluorouracil—pancreatic cancer	0.00114	0.022	CcSEcCtD
Tafluprost—Photophobia—Fluorouracil—pancreatic cancer	0.000989	0.0191	CcSEcCtD
Tafluprost—Eye irritation—Docetaxel—pancreatic cancer	0.00089	0.0172	CcSEcCtD
Tafluprost—Nasopharyngitis—Sunitinib—pancreatic cancer	0.000866	0.0167	CcSEcCtD
Tafluprost—Urinary tract infection—Tamoxifen—pancreatic cancer	0.000847	0.0163	CcSEcCtD
Tafluprost—Lacrimation increased—Docetaxel—pancreatic cancer	0.000825	0.0159	CcSEcCtD
Tafluprost—Urinary tract infection—Sunitinib—pancreatic cancer	0.000726	0.014	CcSEcCtD
Tafluprost—Eye disorder—Erlotinib—pancreatic cancer	0.000724	0.0139	CcSEcCtD
Tafluprost—Nasopharyngitis—Fluorouracil—pancreatic cancer	0.000684	0.0132	CcSEcCtD
Tafluprost—Eye disorder—Sunitinib—pancreatic cancer	0.000626	0.0121	CcSEcCtD
Tafluprost—Cough—Tamoxifen—pancreatic cancer	0.000594	0.0115	CcSEcCtD
Tafluprost—Cough—Erlotinib—pancreatic cancer	0.000588	0.0113	CcSEcCtD
Tafluprost—Urinary tract infection—Fluorouracil—pancreatic cancer	0.000573	0.011	CcSEcCtD
Tafluprost—Lacrimation increased—Epirubicin—pancreatic cancer	0.000556	0.0107	CcSEcCtD
Tafluprost—Rhinitis—Irinotecan—pancreatic cancer	0.000553	0.0107	CcSEcCtD
Tafluprost—Nervous system disorder—Erlotinib—pancreatic cancer	0.000539	0.0104	CcSEcCtD
Tafluprost—Rhinitis—Gemcitabine—pancreatic cancer	0.000539	0.0104	CcSEcCtD
Tafluprost—Rhinitis—Fluorouracil—pancreatic cancer	0.00053	0.0102	CcSEcCtD
Tafluprost—Lacrimation increased—Doxorubicin—pancreatic cancer	0.000515	0.00992	CcSEcCtD
Tafluprost—Cough—Sunitinib—pancreatic cancer	0.000509	0.00981	CcSEcCtD
Tafluprost—Dyspnoea—Tamoxifen—pancreatic cancer	0.000496	0.00955	CcSEcCtD
Tafluprost—Nasopharyngitis—Docetaxel—pancreatic cancer	0.000493	0.00951	CcSEcCtD
Tafluprost—Dyspnoea—Erlotinib—pancreatic cancer	0.00049	0.00945	CcSEcCtD
Tafluprost—Dry eye—Epirubicin—pancreatic cancer	0.000473	0.00913	CcSEcCtD
Tafluprost—Nervous system disorder—Sunitinib—pancreatic cancer	0.000467	0.009	CcSEcCtD
Tafluprost—PTGFR—GPCR downstream signaling—PPY—pancreatic cancer	0.000448	0.00375	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—SST—pancreatic cancer	0.000443	0.00371	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—SSTR2—pancreatic cancer	0.00044	0.00368	CbGpPWpGaD
Tafluprost—Dry eye—Doxorubicin—pancreatic cancer	0.000438	0.00844	CcSEcCtD
Tafluprost—Vision blurred—Fluorouracil—pancreatic cancer	0.000434	0.00836	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—SSTR3—pancreatic cancer	0.000433	0.00362	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—RB1—pancreatic cancer	0.00043	0.0036	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CCKBR—pancreatic cancer	0.000425	0.00355	CbGpPWpGaD
Tafluprost—Dyspnoea—Sunitinib—pancreatic cancer	0.000425	0.00818	CcSEcCtD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—pancreatic cancer	0.00042	0.00352	CbGpPWpGaD
Tafluprost—Cough—Irinotecan—pancreatic cancer	0.000419	0.00808	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—SSTR1—pancreatic cancer	0.000415	0.00347	CbGpPWpGaD
Tafluprost—Eye pain—Epirubicin—pancreatic cancer	0.000412	0.00794	CcSEcCtD
Tafluprost—PTGFR—GPCR ligand binding—CNR1—pancreatic cancer	0.000409	0.00342	CbGpPWpGaD
Tafluprost—Cough—Gemcitabine—pancreatic cancer	0.000409	0.00787	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—PPY—pancreatic cancer	0.000407	0.00341	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—GADD45A—pancreatic cancer	0.000405	0.00339	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—SSTR2—pancreatic cancer	0.000399	0.00334	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—GCG—pancreatic cancer	0.000395	0.0033	CbGpPWpGaD
Tafluprost—Pruritus—Tamoxifen—pancreatic cancer	0.000393	0.00758	CcSEcCtD
Tafluprost—PTGS2—C-MYB transcription factor network—HES1—pancreatic cancer	0.00039	0.00326	CbGpPWpGaD
Tafluprost—Pruritus—Erlotinib—pancreatic cancer	0.000389	0.0075	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—CCKBR—pancreatic cancer	0.000386	0.00323	CbGpPWpGaD
Tafluprost—Nervous system disorder—Irinotecan—pancreatic cancer	0.000385	0.00741	CcSEcCtD
Tafluprost—Rhinitis—Docetaxel—pancreatic cancer	0.000383	0.00737	CcSEcCtD
Tafluprost—Eye pain—Doxorubicin—pancreatic cancer	0.000381	0.00735	CcSEcCtD
Tafluprost—PTGFR—GPCR ligand binding—AGTR1—pancreatic cancer	0.000377	0.00315	CbGpPWpGaD
Tafluprost—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000375	0.00722	CcSEcCtD
Tafluprost—PTGS2—Selenium Micronutrient Network—SOD2—pancreatic cancer	0.000375	0.00314	CbGpPWpGaD
Tafluprost—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000368	0.0071	CcSEcCtD
Tafluprost—PTGFR—GPCR downstream signaling—GAST—pancreatic cancer	0.000365	0.00306	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—pancreatic cancer	0.000362	0.00303	CbGpPWpGaD
Tafluprost—Eye disorder—Docetaxel—pancreatic cancer	0.000357	0.00687	CcSEcCtD
Tafluprost—Dyspnoea—Irinotecan—pancreatic cancer	0.00035	0.00674	CcSEcCtD
Tafluprost—Headache—Tamoxifen—pancreatic cancer	0.000348	0.00671	CcSEcCtD
Tafluprost—PTGFR—GPCR downstream signaling—SCT—pancreatic cancer	0.000346	0.0029	CbGpPWpGaD
Tafluprost—Headache—Erlotinib—pancreatic cancer	0.000345	0.00664	CcSEcCtD
Tafluprost—Dyspnoea—Gemcitabine—pancreatic cancer	0.000341	0.00657	CcSEcCtD
Tafluprost—Pruritus—Sunitinib—pancreatic cancer	0.000337	0.00649	CcSEcCtD
Tafluprost—Dyspnoea—Fluorouracil—pancreatic cancer	0.000335	0.00646	CcSEcCtD
Tafluprost—Nasopharyngitis—Epirubicin—pancreatic cancer	0.000333	0.00641	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—GAST—pancreatic cancer	0.000332	0.00278	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CCK—pancreatic cancer	0.00033	0.00276	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—SHH—pancreatic cancer	0.000325	0.00272	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—GLP1R—pancreatic cancer	0.000322	0.00269	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CNR2—pancreatic cancer	0.000322	0.00269	CbGpPWpGaD
Tafluprost—Asthma—Epirubicin—pancreatic cancer	0.000322	0.0062	CcSEcCtD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—IAPP—pancreatic cancer	0.000321	0.00269	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—pancreatic cancer	0.000321	0.00268	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CCKAR—pancreatic cancer	0.000317	0.00265	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—SCT—pancreatic cancer	0.000314	0.00263	CbGpPWpGaD
Tafluprost—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.000308	0.00593	CcSEcCtD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—pancreatic cancer	0.000307	0.00257	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PRLHR—pancreatic cancer	0.000301	0.00252	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CCK—pancreatic cancer	0.0003	0.00251	CbGpPWpGaD
Tafluprost—Headache—Sunitinib—pancreatic cancer	0.000298	0.00575	CcSEcCtD
Tafluprost—Asthma—Doxorubicin—pancreatic cancer	0.000298	0.00574	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—CNR2—pancreatic cancer	0.000292	0.00245	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—GLP1R—pancreatic cancer	0.000292	0.00245	CbGpPWpGaD
Tafluprost—Cough—Docetaxel—pancreatic cancer	0.00029	0.00559	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—CCKAR—pancreatic cancer	0.000288	0.00241	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—SRC—pancreatic cancer	0.000286	0.00239	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—IAPP—pancreatic cancer	0.000285	0.00239	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ZNRF3—pancreatic cancer	0.000283	0.00237	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ACVR1B—pancreatic cancer	0.000283	0.00237	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—pancreatic cancer	0.000281	0.00235	CbGpPWpGaD
Tafluprost—Urinary tract infection—Epirubicin—pancreatic cancer	0.000279	0.00537	CcSEcCtD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—pancreatic cancer	0.000278	0.00233	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—GADD45A—pancreatic cancer	0.000276	0.00231	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—NRAS—pancreatic cancer	0.000275	0.0023	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PTHLH—pancreatic cancer	0.000274	0.00229	CbGpPWpGaD
Tafluprost—Pruritus—Gemcitabine—pancreatic cancer	0.00027	0.00521	CcSEcCtD
Tafluprost—Nervous system disorder—Docetaxel—pancreatic cancer	0.000266	0.00512	CcSEcCtD
Tafluprost—Pruritus—Fluorouracil—pancreatic cancer	0.000266	0.00512	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—SHH—pancreatic cancer	0.000262	0.00219	CbGpPWpGaD
Tafluprost—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—pancreatic cancer	0.000262	0.00219	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—IAPP—pancreatic cancer	0.000259	0.00217	CbGpPWpGaD
Tafluprost—Rhinitis—Epirubicin—pancreatic cancer	0.000258	0.00497	CcSEcCtD
Tafluprost—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000258	0.00497	CcSEcCtD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—MYC—pancreatic cancer	0.000256	0.00214	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—DTX1—pancreatic cancer	0.000256	0.00214	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SSTR3—pancreatic cancer	0.000256	0.00214	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—EGFR—pancreatic cancer	0.000251	0.0021	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—SST—pancreatic cancer	0.00025	0.0021	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PTHLH—pancreatic cancer	0.000249	0.00208	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PTCH1—pancreatic cancer	0.000249	0.00208	CbGpPWpGaD
Tafluprost—Headache—Irinotecan—pancreatic cancer	0.000246	0.00474	CcSEcCtD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—pancreatic cancer	0.000245	0.00205	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SSTR1—pancreatic cancer	0.000245	0.00205	CbGpPWpGaD
Tafluprost—Dyspnoea—Docetaxel—pancreatic cancer	0.000242	0.00466	CcSEcCtD
Tafluprost—Eye disorder—Epirubicin—pancreatic cancer	0.000241	0.00464	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—PPY—pancreatic cancer	0.00024	0.00201	CbGpPWpGaD
Tafluprost—Headache—Gemcitabine—pancreatic cancer	0.000239	0.00461	CcSEcCtD
Tafluprost—Rhinitis—Doxorubicin—pancreatic cancer	0.000239	0.0046	CcSEcCtD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—TNF—pancreatic cancer	0.000239	0.002	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—KRAS—pancreatic cancer	0.000237	0.00198	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—pancreatic cancer	0.000236	0.00198	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SSTR2—pancreatic cancer	0.000236	0.00197	CbGpPWpGaD
Tafluprost—Headache—Fluorouracil—pancreatic cancer	0.000235	0.00454	CcSEcCtD
Tafluprost—PTGS2—C-MYB transcription factor network—CDKN2A—pancreatic cancer	0.000234	0.00195	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CNR1—pancreatic cancer	0.000231	0.00193	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCKBR—pancreatic cancer	0.000228	0.00191	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—SST—pancreatic cancer	0.000227	0.0019	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000227	0.0019	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	0.000224	0.00187	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—pancreatic cancer	0.000223	0.00187	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—GCG—pancreatic cancer	0.000223	0.00187	CbGpPWpGaD
Tafluprost—Eye disorder—Doxorubicin—pancreatic cancer	0.000223	0.00429	CcSEcCtD
Tafluprost—PTGFR—G alpha (q) signalling events—PIK3CA—pancreatic cancer	0.000217	0.00182	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—DTX4—pancreatic cancer	0.000214	0.00179	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—GLI1—pancreatic cancer	0.000214	0.00179	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—pancreatic cancer	0.000214	0.00179	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000213	0.00178	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	0.000211	0.00177	CbGpPWpGaD
Tafluprost—Vision blurred—Epirubicin—pancreatic cancer	0.000211	0.00407	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—CNR1—pancreatic cancer	0.00021	0.00176	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NRP1—pancreatic cancer	0.000208	0.00174	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000208	0.00174	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—SMAD4—pancreatic cancer	0.000207	0.00173	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—pancreatic cancer	0.000203	0.0017	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—GCG—pancreatic cancer	0.000203	0.0017	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—RB1—pancreatic cancer	0.000202	0.00169	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—HRAS—pancreatic cancer	0.000201	0.00168	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—HEY2—pancreatic cancer	0.000201	0.00168	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—CCND1—pancreatic cancer	0.000197	0.00165	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—GAST—pancreatic cancer	0.000196	0.00164	CbGpPWpGaD
Tafluprost—Cough—Epirubicin—pancreatic cancer	0.000196	0.00377	CcSEcCtD
Tafluprost—Vision blurred—Doxorubicin—pancreatic cancer	0.000195	0.00377	CcSEcCtD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	0.000194	0.00162	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—AGTR1—pancreatic cancer	0.000193	0.00162	CbGpPWpGaD
Tafluprost—Pruritus—Docetaxel—pancreatic cancer	0.000192	0.0037	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—SCT—pancreatic cancer	0.000186	0.00155	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—HEY1—pancreatic cancer	0.000186	0.00155	CbGpPWpGaD
Tafluprost—Cough—Doxorubicin—pancreatic cancer	0.000181	0.00349	CcSEcCtD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	0.00018	0.0015	CbGpPWpGaD
Tafluprost—Nervous system disorder—Epirubicin—pancreatic cancer	0.000179	0.00346	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—CCK—pancreatic cancer	0.000177	0.00148	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CNR2—pancreatic cancer	0.000173	0.00145	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—GLP1R—pancreatic cancer	0.000173	0.00145	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CXCL8—pancreatic cancer	0.000173	0.00144	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—NRAS—pancreatic cancer	0.00017	0.00142	CbGpPWpGaD
Tafluprost—Headache—Docetaxel—pancreatic cancer	0.00017	0.00327	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—CCKAR—pancreatic cancer	0.00017	0.00142	CbGpPWpGaD
Tafluprost—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000166	0.0032	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—JAG2—pancreatic cancer	0.000165	0.00138	CbGpPWpGaD
Tafluprost—Dyspnoea—Epirubicin—pancreatic cancer	0.000163	0.00314	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—MEN1—pancreatic cancer	0.000162	0.00136	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—CXCL8—pancreatic cancer	0.000161	0.00135	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—MYC—pancreatic cancer	0.000158	0.00132	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SHH—pancreatic cancer	0.000155	0.0013	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—CASP3—pancreatic cancer	0.000154	0.00129	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—pancreatic cancer	0.000154	0.00129	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NOTCH4—pancreatic cancer	0.000154	0.00129	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IAPP—pancreatic cancer	0.000153	0.00128	CbGpPWpGaD
Tafluprost—Dyspnoea—Doxorubicin—pancreatic cancer	0.000151	0.00291	CcSEcCtD
Tafluprost—PTGS2—Spinal Cord Injury—CCND1—pancreatic cancer	0.00015	0.00126	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—EGF—pancreatic cancer	0.000147	0.00123	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PTHLH—pancreatic cancer	0.000147	0.00123	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PTCH1—pancreatic cancer	0.000147	0.00123	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—KRAS—pancreatic cancer	0.000146	0.00122	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—MMP9—pancreatic cancer	0.000146	0.00122	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—TNF—pancreatic cancer	0.000142	0.00119	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SST—pancreatic cancer	0.000134	0.00112	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000132	0.00111	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ZNRF3—pancreatic cancer	0.000132	0.0011	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PRSS1—pancreatic cancer	0.000132	0.0011	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—JAG1—pancreatic cancer	0.000131	0.0011	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NOTCH3—pancreatic cancer	0.000131	0.0011	CbGpPWpGaD
Tafluprost—Pruritus—Epirubicin—pancreatic cancer	0.000129	0.00249	CcSEcCtD
Tafluprost—PTGS2—C-MYB transcription factor network—HRAS—pancreatic cancer	0.000124	0.00104	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CNR1—pancreatic cancer	0.000124	0.00104	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—MYC—pancreatic cancer	0.000121	0.00101	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TGFB1—pancreatic cancer	0.00012	0.00101	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PIK3CG—pancreatic cancer	0.00012	0.00101	CbGpPWpGaD
Tafluprost—Pruritus—Doxorubicin—pancreatic cancer	0.00012	0.00231	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—GCG—pancreatic cancer	0.00012	0.001	CbGpPWpGaD
Tafluprost—PTGS2—Disease—DTX1—pancreatic cancer	0.000119	0.000997	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—EGFR—pancreatic cancer	0.000118	0.000987	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000116	0.000974	CbGpPWpGaD
Tafluprost—Headache—Epirubicin—pancreatic cancer	0.000115	0.00221	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—AGTR1—pancreatic cancer	0.000114	0.000956	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—STK11—pancreatic cancer	0.000113	0.000942	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TNF—pancreatic cancer	0.000112	0.00094	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PRSS1—pancreatic cancer	0.00011	0.000923	CbGpPWpGaD
Tafluprost—Headache—Doxorubicin—pancreatic cancer	0.000106	0.00204	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000106	0.000885	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	0.000105	0.000879	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	0.000102	0.000856	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000101	0.000849	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	0.000101	0.000848	CbGpPWpGaD
Tafluprost—PTGS2—Disease—DTX4—pancreatic cancer	9.98e-05	0.000836	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TP53—pancreatic cancer	9.9e-05	0.000829	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	9.87e-05	0.000826	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SMAD4—pancreatic cancer	9.85e-05	0.000825	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CXCL8—pancreatic cancer	9.75e-05	0.000816	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PPP2R5B—pancreatic cancer	9.71e-05	0.000813	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—HES1—pancreatic cancer	9.62e-05	0.000805	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ARG2—pancreatic cancer	9.56e-05	0.000801	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HEY2—pancreatic cancer	9.35e-05	0.000782	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PIK3CB—pancreatic cancer	9.21e-05	0.000771	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	9.15e-05	0.000766	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	8.92e-05	0.000746	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CXCL8—pancreatic cancer	8.85e-05	0.000741	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HEY1—pancreatic cancer	8.65e-05	0.000724	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TERT—pancreatic cancer	8.43e-05	0.000706	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—TYMP—pancreatic cancer	8.36e-05	0.0007	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	8.2e-05	0.000687	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	8.18e-05	0.000685	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—HIF1A—pancreatic cancer	8.06e-05	0.000675	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TSC2—pancreatic cancer	8.04e-05	0.000673	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	8.02e-05	0.000672	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—APOE—pancreatic cancer	7.87e-05	0.000659	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—KDR—pancreatic cancer	7.71e-05	0.000646	CbGpPWpGaD
Tafluprost—PTGS2—Disease—JAG2—pancreatic cancer	7.68e-05	0.000642	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	7.64e-05	0.00064	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	7.58e-05	0.000634	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MEN1—pancreatic cancer	7.56e-05	0.000633	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SLC2A2—pancreatic cancer	7.51e-05	0.000629	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NFKBIA—pancreatic cancer	7.34e-05	0.000614	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NOTCH1—pancreatic cancer	7.26e-05	0.000608	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SHH—pancreatic cancer	7.22e-05	0.000604	CbGpPWpGaD
Tafluprost—PTGS2—Disease—IAPP—pancreatic cancer	7.13e-05	0.000597	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PIK3CG—pancreatic cancer	7.1e-05	0.000595	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—NRAS—pancreatic cancer	7.1e-05	0.000595	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—EGF—pancreatic cancer	7.02e-05	0.000588	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	6.96e-05	0.000583	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	6.9e-05	0.000577	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HSPA1B—pancreatic cancer	6.84e-05	0.000573	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GLP1R—pancreatic cancer	6.74e-05	0.000564	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	6.74e-05	0.000564	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—DPYD—pancreatic cancer	6.63e-05	0.000555	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—EGFR—pancreatic cancer	6.47e-05	0.000542	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—SLC2A2—pancreatic cancer	6.29e-05	0.000527	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PIK3CD—pancreatic cancer	6.24e-05	0.000523	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	6.23e-05	0.000521	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.19e-05	0.000518	CbGpPWpGaD
Tafluprost—PTGS2—Disease—JAG1—pancreatic cancer	6.12e-05	0.000513	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—KRAS—pancreatic cancer	6.11e-05	0.000512	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	6.01e-05	0.000503	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CD44—pancreatic cancer	5.82e-05	0.000487	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HSPA1A—pancreatic cancer	5.77e-05	0.000483	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	5.69e-05	0.000476	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PIK3CA—pancreatic cancer	5.62e-05	0.00047	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	5.47e-05	0.000458	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PIK3CB—pancreatic cancer	5.44e-05	0.000456	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CXCL8—pancreatic cancer	5.23e-05	0.000438	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—HRAS—pancreatic cancer	5.2e-05	0.000435	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—AKT1—pancreatic cancer	5.05e-05	0.000423	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CASP3—pancreatic cancer	5.01e-05	0.000419	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCND1—pancreatic cancer	4.87e-05	0.000408	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CD44—pancreatic cancer	4.87e-05	0.000408	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CTNNB1—pancreatic cancer	4.83e-05	0.000404	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	4.77e-05	0.000399	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MMP9—pancreatic cancer	4.73e-05	0.000396	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PTEN—pancreatic cancer	4.7e-05	0.000394	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GCG—pancreatic cancer	4.67e-05	0.000391	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SMAD4—pancreatic cancer	4.59e-05	0.000384	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—AKT1—pancreatic cancer	4.59e-05	0.000384	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HES1—pancreatic cancer	4.48e-05	0.000375	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—STK11—pancreatic cancer	4.39e-05	0.000368	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SRC—pancreatic cancer	4.36e-05	0.000365	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—VEGFA—pancreatic cancer	4.25e-05	0.000356	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—STAT3—pancreatic cancer	4.21e-05	0.000352	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NRAS—pancreatic cancer	4.2e-05	0.000351	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	4.12e-05	0.000345	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TERT—pancreatic cancer	3.93e-05	0.000329	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MYC—pancreatic cancer	3.91e-05	0.000327	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TGFB1—pancreatic cancer	3.9e-05	0.000326	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—EGFR—pancreatic cancer	3.82e-05	0.00032	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—TYMS—pancreatic cancer	3.78e-05	0.000316	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HIF1A—pancreatic cancer	3.76e-05	0.000315	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TSC2—pancreatic cancer	3.75e-05	0.000314	CbGpPWpGaD
Tafluprost—PTGS2—Disease—APOE—pancreatic cancer	3.67e-05	0.000307	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—KRAS—pancreatic cancer	3.61e-05	0.000302	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NOTCH1—pancreatic cancer	3.39e-05	0.000283	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PIK3CA—pancreatic cancer	3.32e-05	0.000278	CbGpPWpGaD
Tafluprost—PTGS2—Disease—EGF—pancreatic cancer	3.27e-05	0.000274	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TP53—pancreatic cancer	3.21e-05	0.000269	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—APOE—pancreatic cancer	3.07e-05	0.000257	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—HRAS—pancreatic cancer	3.07e-05	0.000257	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PIK3CD—pancreatic cancer	2.91e-05	0.000244	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.91e-05	0.000243	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PIK3CG—pancreatic cancer	2.77e-05	0.000232	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—AKT1—pancreatic cancer	2.71e-05	0.000227	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PPARG—pancreatic cancer	2.68e-05	0.000224	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PIK3CB—pancreatic cancer	2.54e-05	0.000212	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PIK3CD—pancreatic cancer	2.44e-05	0.000204	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CTNNB1—pancreatic cancer	2.25e-05	0.000188	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PTEN—pancreatic cancer	2.19e-05	0.000183	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PIK3CB—pancreatic cancer	2.12e-05	0.000178	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SRC—pancreatic cancer	2.03e-05	0.00017	CbGpPWpGaD
Tafluprost—PTGS2—Disease—STAT3—pancreatic cancer	1.96e-05	0.000164	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NRAS—pancreatic cancer	1.96e-05	0.000164	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PTEN—pancreatic cancer	1.84e-05	0.000154	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MYC—pancreatic cancer	1.82e-05	0.000152	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TGFB1—pancreatic cancer	1.82e-05	0.000152	CbGpPWpGaD
Tafluprost—PTGS2—Disease—EGFR—pancreatic cancer	1.78e-05	0.000149	CbGpPWpGaD
Tafluprost—PTGS2—Disease—KRAS—pancreatic cancer	1.68e-05	0.000141	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PIK3CA—pancreatic cancer	1.55e-05	0.000129	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HRAS—pancreatic cancer	1.43e-05	0.00012	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PIK3CA—pancreatic cancer	1.29e-05	0.000108	CbGpPWpGaD
Tafluprost—PTGS2—Disease—AKT1—pancreatic cancer	1.26e-05	0.000106	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—AKT1—pancreatic cancer	1.06e-05	8.86e-05	CbGpPWpGaD
